Login

Financial Snapshot

Revenue
TTM
$49.59M
Gross Margin
TTM
85.13%
Net Income
TTM
-$194.0M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
303.54%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
81.78M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$108.5M

Stock Price

Loading...
Market Cap: $380.49 Million

About Verastem Inc

Verastem Inc (NASDAQ: VSTM) is a commercial-stage oncology biopharmaceutical company that develops and sells targeted cancer therapies. Revenue is generated through product sales of AVMAPKI FAKZYNJA CO-PACK, distributed via specialty pharmacy and specialty distributor channels, with net revenue reduced by trade discounts, allowances, chargebacks, and third-party payer fees. Verastem became a public company on January 27, 2012, and is incorporated in Delaware. As of the fiscal year ended December 31, 2025, the company continued to incur operating losses, with cash used in operating activities of $137.5 million in FY2025 compared to $104.8 million in FY2024. Accumulated losses since inception reflect a pre-profitability stage despite active commercialization. The company has funded operations through equity offerings, convertible preferred stock, debt facilities, and at-the-market programs. No competitors are named in the available filing excerpts.

Revenue model
Product revenue from sales of AVMAPKI FAKZYNJA CO-PACK to specialty pharmacy and specialty distributor customers, net of trade discounts, prompt-payment allowances, third-party payer chargebacks, and distribution service fees recorded as revenue reductions (FY2025, per 10-K filed 2026-03-04).
Products and services
AVMAPKI FAKZYNJA CO-PACK: a co-packaged oncology product sold through specialty pharmacy and specialty distributor channels as of FY2025.
Customers and end markets
Specialty pharmacies and specialty distributors serve as direct customers. End market is oncology patients covered by Medicare, Medicaid, and third-party commercial payers. Reimbursement from government and commercial payers is material to product pricing and demand.
Value-chain role
Drug developer and commercial-stage manufacturer selling an approved oncology therapy through specialty distribution channels, subject to FDA post-marketing requirements and promotional material review.

Source: SEC 10-K, filed 2026-03-04

Industry: Pharmaceutical Preparations Peers: Actinium Pharmaceuticals Inc Acumen Pharmaceuticals Inc Akouos, Inc. Armata Pharmaceuticals Inc Ardelyx Inc LENZ Therapeutics Inc Oyster Point Pharma, Inc. ARS Pharmaceuticals Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support